CAS 81624-55-7
:N,N,N',N'-tetrakis[(6-metil-1H-benzimidazol-2-il)metil]etano-1,2-diammina
- Prezzo più basso
- Prezzo più alto
- Purezza più bassa
- Purezza più alta
- Consegna più veloce
NSC348884
CAS:NSC348884, a nucleophosmin inhibitor, disrupts oligomers, induces apoptosis, and inhibits cancer cell growth (IC50: 1.7-4.0 μM).Formula:C38H40N10Purezza:98.69% - 99.91%Colore e forma:SolidPeso molecolare:636.7912NSC348884
CAS:N1,N1,N2,N2-Tetrakis((6-methyl-1H-benzo[d]imidazol-2-yl)methyl)ethane-1,2-diamineFormula:C38H40N10Purezza:99%Peso molecolare:636.79N1,N1,N2,N2-Tetrakis((6-methyl-1H-benzo[d]imidazol-2-yl)methyl)ethane-1,2-diamine
CAS:Purezza:99%Peso molecolare:636.8079834Ref: 10-F869984
1gPrezzo su richiesta10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiesta250mgPrezzo su richiesta5mg35,00€NSC348884
CAS:NSC348884 is a novel anti-cancer drug that is an inhibitor of RNA polymerase. It has been shown to inhibit cellular transformation and viability in human leukemia HL-60 cells and prostate cancer cells, as well as inducing apoptosis. The mechanism of action of NSC348884 may be mediated through the induction of reactive oxygen species (ROS), activation of caspases, and modulation of signal transduction pathways. NSC348884 has also been shown to induce a variety of transcriptional effects on tumor cells, including upregulation or downregulation of genes involved in cell cycle regulation and apoptosis. This drug is also efficacious against brain tumors with malignant characteristics and breast cancer cells that are resistant to monoclonal antibody therapy.
Formula:C38H40N10Purezza:Min. 95%Peso molecolare:636.79 g/mol






